Corteva, Inc. 2025 Q2 10-Q Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2025, for Corteva, Inc. (CTVA) and its subsidiary EIDP, Inc. Corteva operates in two reportable segments: Seed and Crop Protection. The filing includes a combined report for both entities, with EIDP filing under reduced disclosure format as a wholly-owned subsidiary. The company is a large accelerated filer.
Key Financial Metrics
| Metric | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Net Sales | $6,456 million | $6,112 million | $10,873 million | $10,604 million |
| Net Income (Attributable to Corteva) | $1,314 million | $1,053 million | $1,966 million | $1,472 million |
| Diluted EPS (Continuing Ops) | $2.02 | $1.51 | $2.98 | $2.03 |
| Operating EBITDA (Non-GAAP) | $2,164 million | $1,917 million | $3,353 million | $2,951 million |
| Cash & Equivalents | $2,065 million | $1,839 million | $2,065 million | $1,839 million |
| Total Debt | $3,629 million | $4,724 million | $3,629 million | $4,724 million |
| Operating Cash Flow (Continuing) | Not provided for Q2 | Not provided for Q2 | $(1,139) million | $(1,999) million |
Note: Operating cash flow for the six months ended June 30, 2025, was negative due to seasonal working capital needs, primarily driven by customer prepayments and inventory management.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 6% in Q2 and 3% YTD, driven by volume growth (6% in Q2, 4% YTD) and price increases (1% in both periods), partially offset by unfavorable currency impacts (-1% in Q2, -2% YTD).
- Profitability: Net income attributable to Corteva rose 25% in Q2 and 34% YTD. Operating EBITDA margins improved significantly, with Seed segment margins up 185 basis points (Q2) and Crop Protection margins up 310 basis points (Q2).
- Cost Management: Cost of goods sold (COGS) as a percentage of net sales decreased to 45% in Q2 (from 48% in Q2 2024) and 49% YTD (from 52% YTD 2024), aided by raw material deflation and lower royalty expenses.
- Restructuring: Restructuring and asset-related charges decreased to $79 million in Q2 (from $92 million) and $101 million YTD (from $167 million), primarily related to the Crop Protection Operations Strategy Restructuring Program.
- Discontinued Operations: The company recorded a loss of $66 million in Q2 and $77 million YTD from discontinued operations, driven by charges related to the MOU with Chemours and DuPont (NJ Statewide Settlement and PFAS remediation).
Guidance, Outlook, and Risks
- Capital Allocation: The company returned approximately $750 million to shareholders in the first half of 2025 via dividends and share repurchases. A $3 billion share repurchase program was authorized in November 2024; the company expects to repurchase approximately $1 billion in total for the full year 2025.
- Dividends: The Board authorized a quarterly dividend of $0.18 per share in July 2025, a 5.9% increase from the previous $0.17 rate.
- Restructuring Outlook: The Crop Protection Operations Strategy Restructuring Program is expected to be substantially complete by the end of 2026, with total pre-tax charges estimated between $650 million and $700 million. The program aims to deliver $180 million in run-rate savings by 2027.
- Regulatory & Tax: The company is evaluating the impact of the "One Big Beautiful Bill Act" (OBBBA) signed July 4, 2025, which reinstates expensing of domestic R&D expenditures, expected to favorably impact cash tax outflows in H2 2025.
- Key Risks:
- Legal Proceedings: Significant exposure remains regarding PFAS litigation (NJ Statewide Settlement, Ohio MDL, Netherlands cases) and antitrust investigations (FTC lawsuit). The company recorded a $72 million pre-tax loss in Q2 related to the NJ Statewide Settlement.
- Regulatory Delays: Staff and funding reductions at the EPA, USDA, and FDA could delay regulatory approvals for genetically modified seeds and crop protection products.
- Currency: Continued volatility in the Brazilian Real, Canadian Dollar, and Turkish Lira poses a risk to reported results.
Investor Verification Checklist
- Working Capital Seasonality: Verify the impact of seasonal receivables and inventory build-up on operating cash flow, which resulted in a negative operating cash flow of $(1,139) million YTD.
- Restructuring Progress: Monitor the execution of the Crop Protection Operations Strategy Restructuring Program and the realization of the projected $180 million in annual savings.
- PFAS Litigation Exposure: Review the status of the NJ Statewide Settlement and other PFAS-related claims, as these continue to generate significant charges in discontinued operations.
- Antitrust Developments: Track the FTC lawsuit and related private class actions, with trials expected to begin in 2026.
- Share Repurchase Execution: Confirm the pace of share buybacks against the $1 billion full-year 2025 target.